Neurocrine Biosciences (NBIX) Return on Equity [ROE] (2009 - 2026)
Neurocrine Biosciences (NBIX) reported Return on Equity [ROE] of 18.55% for Q3 2026, up 3.53 percentage points from 15.02% a year earlier but down 1.32 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Return on Equity [ROE] (2009 - 2026) Analysis & Trends
For FY2025, Neurocrine Biosciences posted Return on Equity [ROE] of 16.38%, up 2.23 percentage points from FY2024.
- Return on Equity [ROE] has increased for four consecutive years, though with a five-year change of -29.82 percentage points (FY2020 to FY2025).
- By year, Return on Equity [ROE] came in at 14.16% in FY2024 (+1.48 pp), 12.68% in FY2023 (+2.65 pp), 10.03% in FY2022 (+2.86 pp) and 7.17% in FY2021 (-39.04 pp).
- Five-year quarterly Return on Equity [ROE] spans a low of 0.87% in Q2 2022 and a high of 20.08% in Q1 2026.
- Year over year, Return on Equity [ROE] has now increased in each of the last five quarters, with an average year-over-year change of +2.17 percentage points over the last eight quarters.
- The high point for year-over-year Return on Equity [ROE] in five years was Q1 2024 (a gain of 12.24 percentage points); the low point was Q4 2021 (a drop of 35.61 percentage points).
- Per Business Quant data, the three quarters before Q3 2026 came in at 19.87% (Q2 2026), 20.08% (Q1 2026) and 15.30% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 4.66% |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 18.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 18.32% |
| Jun 30, 2026 | 19.66% |
| Mar 31, 2026 | 19.82% |
| Dec 31, 2025 | 15.53% |
| Sep 30, 2025 | 14.98% |
| Jun 30, 2025 | 13.70% |
| Mar 31, 2025 | 12.16% |
| Dec 31, 2024 | 12.81% |
| Sep 30, 2024 | 15.38% |
| Jun 30, 2024 | 14.01% |
| Mar 31, 2024 | 16.27% |
| Dec 31, 2023 | 12.50% |
| Sep 30, 2023 | 10.55% |
| Jun 30, 2023 | 10.60% |
| Mar 31, 2023 | 4.16% |
| Dec 31, 2022 | 9.12% |
| Sep 30, 2022 | 2.95% |
| Jun 30, 2022 | -0.05% |
| Mar 31, 2022 | 4.42% |
| Dec 31, 2021 | 6.33% |
API Access
Neurocrine Biosciences Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();